THE PROJECT IS BASED ON THE RECENT DISCOVERY OF ACE2 AS THE ENTRY POINT OF SARS-COV-2 VIRUS IN THE HOST CELLS, BEING THE BLOCKADE OF THIS PROCESS OUR STRATEGY FOR TREATING THE INFECTION. THUS, OUR MAJOR AIM IS FINDING EXISTING DRUGS THAT WILL RENDER REPURPOSING THERAPEUTICS FOR COVID-19. THE PROJECT WILL START WITH DRUG REPURPOSING FOR IDENTIFYING ALREADY AUTHORIZED DRUGS THAT MAY BE USEFUL FOR TREATING COVID-19. THIS WILL ALLOW TO RAPIDLY ENTER IN PROOF-OF-CONCEPT CLINICAL TRIALS FOR TARGET AND THERAPEUTIC ENGAGEMENT.